I own both CUR and ATHX. I think that both companies have merit. Just a couple of clarifications:
-- CUR is actually in human trials for Stroke in China currently. If effective, they anticipate a much faster approval path than here in the US, as well as a large market.
-- CUR's current MV is being driven mainly by its ALS treatment now in Phase II (which, by the way, is for the same drug being used for the Rat Stroke study). If this is successful, the treatment immediately takes center stage as the only viable ALS treatment. In that case, 360M will be way too low a number for its valuation.